Core Insights - China Biotechnology Services (08037) announced significant progress for its flagship project, Pengbo (Hainan) Boron Neutron Hospital, located in the Boao Lecheng International Medical Tourism Pilot Zone, with the NeuCure neutron irradiation system achieving its first beam output on November 20, 2025 [1] - The NeuCure system is the only boron neutron therapy system globally that has received formal medical device registration and can be directly applied in routine clinical treatment, not just in clinical trials [1] - Clinical treatment services are expected to officially commence in the first quarter of 2026, supported by favorable policies from the Boao Lecheng zone [1] Project Milestones - The successful beam output confirms that the core components of the system meet design specifications, marking a transition from equipment installation to beam debugging [1] - This milestone lays a solid foundation for subsequent key tasks, including precise neutron dose rate control, beam physics validation, and biological effect assessment [1] - The project aims to provide safe and precise boron neutron therapy services for cancer patients, ensuring high standards in clinical treatment progression [1]

（於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 自願公告 硼中子治療裝置成功實現首次出束 本自願公告乃由中國生物科技服務控股有限公司（「本公司」，連同其附屬公司， 統稱為「本集團」）作出，以知會本公司股東及潛在投資者有關本集團的最新業務 發展情況。 1 此次出束成功，驗證了系統核心部件各項參數均達到設計指標，標誌著該項目正 式從設備安裝正式轉入束流調試。這一關鍵節點的達成，為後續中子注量率精準 調控、束流物理驗證以及生物學效應評估等核心工作奠定了堅實基礎，也確保了 設備能夠按既定計劃高標準推進臨床治療，為癌症患者提供安全及精准的硼中子 治療服務。 承董事會命 中國生物科技服務控股有限公司 本集團位於中國海南博鰲樂城國際醫療旅遊先行區之旗艦項目 — 鵬博（海南）硼 中子醫 ...

致：香港交易及結算所有限公司 公司名稱: 中國生物科技服務控股有限公司 呈交日期: 2025年11月5日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08037 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.1 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.1 HKD | | 200,000,000 | 本月底法定/註冊股本總額： HKD 200, ...

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 延長有關 採納股份獎勵計劃 及認購附屬公司股份的 獲豁免關連交易的 最後截止日期 謹此提述中國生物科技服務控股有限公司（「本公司」）日期為二零二四年八月五日 的公告（「該公告」），內容有關（其中包括）鵬博（海南）採納股份獎勵計劃以及就 嘉博眾治（海南）認購Dynamic Healthcare已發行股本的9%訂立認購協議的獲豁免 關連交易。除另有界定者外，於本公告內所採用的詞彙與該公告內所界定者具有 相同涵義。 主席兼執行董事 劉小林 香港，二零二五年十月三十一日 1 於本公告日期，董事會包括四名執行董事，即劉小林先生（主席）、何詢先生、 黃嵩先生及尹燁博士；及三名獨立非執行董事，即鄢國祥先生、郭圓濤博士及 張曉博士。 本公 ...

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 (5) 其他集資活動正進行中 有關實施行動計劃以解決無法表示審計意見之季度更新 中國生物科技服務控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」）董 事（「董事」）會（「董事會」）謹此就有關解決本公司核數師對截至二零二四年十二月 三十一日止年度本集團綜合財務報表所作有關持續經營的無法表示意見（「無法表 示意見」）的行動計劃（「行動計劃」）實施情況提供季度更新。除非文義另有所指， 否則本公告所用詞彙與本公司截至二零二四年十二月三十一日止年度的年報所用 者具有相同涵義。 (1) 銀行借款 管理層已繼續與不同銀行就銀行融資續期及取得額外資金進行磋商。於二零 二五年九月，海南農村商業銀行股份有限公司瓊海支行亦已向鵬博（海南 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生物科技服務控股有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08037 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.1 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.1 | HKD | | 200,000,000 | 本月底法定 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 就額外擔保更改可換股債券之條款 謹此提述中國生物科技服務控股有限公司日期分別為二零二四年十二月十七日及 二零二四年十二月二十七日之公告，內容有關根據一般授權發行可換股債券。除 文義另有所指外，於本公告內所採用之詞彙與上述公告內所界定者具有相同涵義。 截至本公告日期，尚未有任何可換股債券已經獲轉換為換股股份，而尚未償還可 換股債券之本金為6,000,000美元，其全數於二零二六年十二月二十七日到期償還。 額外擔保 於二零二五年九月二十六日，本公司與認購人訂立修訂協議，對可換股債券之條 款及條件作出若干修訂（「該等更改」），據此，除由鵬博（海南）硼中子醫療科技有 限公司提供公司擔保外，可換股債券須由以認購人為受益人的兩項額外擔 ...

Dear Non-registered Shareholder(s)(Note 1) , 26 September 2025 The following document(s) of China Biotech Services Holdings Limited ("Company") has/have been prepared in English and Chinese and is/are available on the websites of the Company at www.cbshhk.com and The Stock Exchange of Hong Kong Limited at www.hkexnews.hk (collectively "Websites"):- • Interim Report 2025 You may at any time send your request in writing to the Company (c/o its Hong Kong Branch Share Registrar, Union Registrars Limited ("Hong ...

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (Incorporated in the Cayman Islands and continued in Bermuda with limited liability) （於開曼群島註冊成立並在百慕達繼續營業之有限公司） (Stock Code 股份代號: 8037) NOTIFICATION LETTER 通知信函 Dear Registered Shareholder(s), 26 September 2025 各位登記股東： 中國生物科技服務控股有限公司（「本公司」）下述文件已以中、英文版本編制及於本公司之網站 (www.cbshhk.com) 及香港聯合交易所有限公司之網 站 (www.hkexnews.hk) （統稱「該等網站」）刊載:- • 中期報告 2025 如 閣下並未提供電郵地址或電郵地址無效，並現在希望收取有關公司通訊於該等網站發佈的電郵通知，以代替日後書面通知印刷本，請 閣下填妥本 函背面的回條，並在回條上填寫所需資料及簽名，然後把回條以電郵至 8037-corpcomm@uni ...

Financial Performance - Revenue for the six months ended June 30, 2025, was HKD 38,872,000, an increase of 19.0% compared to HKD 32,449,000 for the same period in 2024[4] - Gross profit for the same period was HKD 2,542,000, a significant recovery from a gross loss of HKD 3,107,000 in 2024[4] - Operating loss decreased to HKD 19,308,000 from HKD 124,588,000 year-on-year, indicating improved operational efficiency[4] - The net loss attributable to owners of the company was HKD 32,006,000, down from HKD 79,917,000 in the previous year, reflecting a 59.9% reduction[5] - The company reported a basic and diluted loss per share of HKD 0.033, an improvement from HKD 0.083 in the previous year[5] - Other comprehensive income for the period was HKD 6,251,000, compared to a loss of HKD 7,242,000 in 2024, showing a positive shift in financial performance[5] - The total comprehensive loss for the period was HKD (30,502) thousand, which includes a loss of HKD (36,753) thousand attributable to owners of the company[10] - The group recorded a loss of approximately HKD 36,753,000 for the six months ended June 30, 2025, compared to a loss of HKD 125,731,000 for the same period in 2024[18][24] Assets and Liabilities - Total assets as of June 30, 2025, amounted to HKD 538,426,000, a slight increase from HKD 529,955,000 at the end of 2024[8] - Non-current assets increased to HKD 502,598,000 from HKD 466,860,000, primarily driven by growth in property, plant, and equipment[7] - Current liabilities rose to HKD 195,691,000 from HKD 192,614,000, indicating a stable liquidity position despite increased operational activities[8] - The group has total borrowings and lease liabilities of approximately HKD 161,096,000 and HKD 9,418,000, respectively, with cash and bank balances of only HKD 11,290,000[18][19] - As of June 30, 2025, total equity attributable to owners of the company was HKD 211,886 thousand, down from HKD 242,388 thousand at the beginning of the period[10] - The company’s accumulated losses increased to HKD (566,473) thousand as of June 30, 2025, compared to HKD (534,467) thousand at the beginning of the period[10] Cash Flow - For the six months ended June 30, 2025, the net cash used in operating activities was HKD (4,936) thousand, a significant improvement from HKD (95,539) thousand in the same period of 2024[12] - The net cash used in investing activities for the same period was HKD (22,769) thousand, compared to HKD (61,468) thousand in 2024, indicating a reduction in investment outflows[12] - Financing activities generated a net cash inflow of HKD 23,128 thousand, down from HKD 118,558 thousand in the previous year, reflecting a decrease in financing activities[12] Operational Efficiency - The company continues to focus on research and development, with R&D expenses reduced to HKD 5,965,000 from HKD 17,593,000, reflecting a strategic shift towards cost management[4] - Sales and distribution expenses decreased by approximately 44.6%, from about HKD 6.5 million to HKD 3.6 million, primarily due to reduced employee costs during the reporting period[80] - Administrative expenses for the first half of 2025 were approximately HKD 34.0 million, a decrease of about 52.0% compared to HKD 70.9 million in the first half of 2024, primarily due to reduced employee costs and a one-time legal claim in the previous period[82] Segment Performance - Revenue from medical laboratory testing and health check services was HKD 16,164,000, down 18.5% from HKD 19,729,000 in the previous year[21][24] - Insurance brokerage services generated revenue of HKD 22,640,000, a significant increase of 84.5% compared to HKD 12,255,000 in the prior year[21][24] - The group reported a segment loss of HKD 18,320,000 for the six months ended June 30, 2025, compared to a segment loss of HKD 100,949,000 for the same period in 2024[24] Financing and Capital Structure - The group is actively seeking alternative financing options, including share placements and issuing convertible bonds, to strengthen equity and support growth[20] - The company issued convertible bonds totaling USD 6,000,000 (approximately HKD 47,100,000) on December 27, 2024, with a conversion price of HKD 1.20 per share[49] - As of June 30, 2025, the liability component of the convertible bonds was HKD 42,919,000, an increase from HKD 41,635,000 as of December 31, 2024[50] - Bank borrowings rose to HKD 33,981,000 as of June 30, 2025, compared to HKD 25,981,000 as of December 31, 2024, reflecting an increase of 30.5%[53] - Total borrowings increased to HKD 161,096,000 as of June 30, 2025, up from HKD 138,693,000 as of December 31, 2024, representing a growth of 16.1%[53] Strategic Initiatives - The company is collaborating with AXA Insurance to develop a comprehensive medical insurance product covering boron neutron capture therapy costs, aimed at increasing public awareness and accessibility[91] - Partnerships have been established with leading hospitals to facilitate patient referrals to the boron neutron capture therapy center, enhancing awareness and accessibility for cancer patients[92] - The company aims to commercialize LY007 and accelerate its development, including entering into domestic phase II clinical trials and commercial partnerships[101] Corporate Governance - The audit committee has reviewed the group's unaudited interim results for the period and confirmed compliance with applicable accounting standards and GEM listing rules[162] - The company has maintained high standards of corporate governance and compliance with legal and regulatory requirements[156] - The board consists of four executive directors and three independent non-executive directors as of August 27, 2025[169]